How New Developments Impact Diagnosis in Existing Renal Neoplasms

Mahmut Akgul; Sean R Williamson

doi:10.1016/j.path.2022.07.005

How New Developments Impact Diagnosis in Existing Renal Neoplasms

Surg Pathol Clin. 2022 Dec;15(4):695-711. doi: 10.1016/j.path.2022.07.005. Epub 2022 Oct 13.

Authors

Mahmut Akgul¹, Sean R Williamson²

Affiliations

¹ Department of Pathology and Laboratory Medicine, Albany Medical Center, 47 New Scotland Ave, Room F110S, MC81 Albany, NY 12208, USA.
² Department of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Mail Code L25 Cleveland, OH 44195, USA. Electronic address: williamson.sean@outlook.com.

PMID: 36344184
DOI: 10.1016/j.path.2022.07.005

Abstract

In recent years, several emerging diagnostic entities have been described in renal cell carcinoma (RCC). However, our understanding of well-known and established entities has also grown. Clear cell papillary RCC is now relabeled as a tumor rather than carcinoma in view of its nonaggressive behavior. Renal tumors with a predominantly infiltrative pattern are very important for recognition, as most of these have aggressive behavior, including fumarate hydratase-deficient RCC, SMARCB1-deficient medullary carcinoma, collecting duct carcinoma, urothelial carcinoma, and metastases from other cancers.

Keywords: Chromophobe renal cell carcinoma; Clear cell renal cell carcinoma; Oncocytoma; Papillary renal cell carcinoma; Renal cell carcinoma.

Publication types

Review

MeSH terms

Carcinoma, Medullary* / diagnosis
Carcinoma, Renal Cell* / diagnosis
Carcinoma, Renal Cell* / genetics
Carcinoma, Renal Cell* / pathology
Carcinoma, Transitional Cell*
Diagnosis, Differential
Humans
Kidney Neoplasms* / diagnosis
Kidney Neoplasms* / genetics
Kidney Neoplasms* / pathology
Urinary Bladder Neoplasms*